news release
- company news
recently, our company on hypertension line, preferred drug yitai® perindopril tert-butylamine tablets and shangyao dongying ( jiangsu ) pharmaceutical co., ltd. to reach a strategic cooperation, access to the product exclusive national agency.
morewe have recently entered into a partnership with fuso teikoku qingdao co.,
morein june 2018, we held the “clinical investigator meeting on rabeprazole sodium for injection” in guangzhou. at the meeting, the concerned sites discussed the clinical study protocol regarding rabeprazole sodium for injection.
morethe second heilongjiang health longjiang carnival and the 2018 heilongjiang international health industry expo opened on october 23 at the harbin international convention and exhibition sports center. the health expo was sponsored by heilongjiang pr
morethe 2018 guangdong medical association academic conference on gastroenterology, sponsored by the guangdong medical association
october 4, 2018 shionogi & co., ltd, osaka, japan, announced the latest results of the global phase iii study evaluating the anti-influenza drug baloxavir in high-risk individuals with influenza-related complications (capstone-2) at idweek, held
address5/f, jihao building, 1086 shennan east road, luohu district, shenzhen
adverse drug reactions / event feedback hotline025-6816 1304
adverse drug reactions / event feedback mailgvp@changao.com
official wechat account mobile page